Ropes & Gray represented the underwriters in Rhythm Pharmaceuticals’ (Nasdaq: RYTM) $201 million equity offering, including the full exercise of the underwriters’ $26 million option to purchase additional shares. The transaction closed on July 11.
Rhythm is a global commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases.
The team was led by capital markets partners Tom Danielski and Tristan VanDeventer.
